An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia

Abstract

The over-expression of the Bcl-2 protein is a common feature of many solid cancers and hematological malignancies, and it is typically associated with poor prognosis and resistance to chemotherapy. Bcl-2-specific inhibitors, such as venetoclax, have recently been approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and they are showing promise in clinical trials as a targeted therapy for patients with relapsed or refractory acute myeloid leukemia (AML). However, successful treatment of AML with Bcl-2-specific inhibitors is often followed by the rapid development of drug resistance. An emerging paradigm for overcoming drug resistance in cancer treatment is through the targeting of mitochondrial energetics and metabolism. In AML in particular, it was recently observed that inhibition of mitochondrial translation via administration of the antibiotic tedizolid significantly affects mitochondrial bioenergetics, activating the integrated stress response (ISR) and subsequently sensitizing drug-resistant AML cells to venetoclax. Here we develop an integrative systems biology approach to acquire a deeper understanding of the molecular mechanisms behind this process, and in particular, of the specific role of the ISR in the commitment of cells to apoptosis. Our multi-scale mathematical model couples the ISR to the intrinsic apoptosis pathway in venetoclax-resistant AML cells, includes the metabolic effects of treatment, and integrates RNA, protein level, and cellular viability data. Using the mathematical model, we identify the dominant mechanisms by which ISR activation helps to overcome venetoclax resistance, and we study the temporal sequencing of combination treatment to determine the most efficient and robust combination treatment protocol.

A Leukemic Target with a Thousand Faces: The Mitochondria

“…Due to its relevance, the biological basis for Venetoclax resistance has been extensively studied. To date we can identify the main mechanisms involved (Figure 2): occurrence of Bcl-2 mutations (e.g., Gly101Va) that cause a reduction in Venetoclax affinity for Bcl-2 [117], upregulation of other anti-apoptotic proteins like BCL-XL or MCL-1, which can provide alternative survival signals for the leukemia cells [118], reduced expression of proapoptotic proteins crucial for Venetoclax-induced apoptosis [119], and increased OXPHOS or alternative sources for energy metabolism [120]. To overcome resistance to Venetoclax in leukemia, a variety of approaches are under investigation.…”